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Özet
Amaç: Meme kanseri insidensi yaşla birlikte artar ve hastaların yaklaşık %85’i 
50 yaşından sonra tanı alır. Genç hastalarda meme kanserinin klinik seyri ile-
ri yaştaki hastalara göre daha kötüdür. Çalışmamızın amacı çok erken yaş 
meme kanserli hastalar ile ileri yaş meme kanserli hastalar arasında Bcl-2 
ekspresyonu ve Ki-67 proliferasyon indeksi açısından fark olup olmadığının 
belirlenmesi ve eğer belirlenebilirse bu farkın klinik öneminin araştırılması-
dır. Gereç ve Yöntem: Antalya Eğitim ve Araştırma Hastanesi’nde 2008-2010 
yılları arasında meme kanseri tanısı almış 35 yaş ve altı 15 hasta (Grup A) 
ile 35 yaş üzeri meme kanserli 30 hasta (Grup B) çalışmaya alındı. Bulgular: 
Bcl-2 ekspresyonu 33 hastada (73.3%)  pozitif, 12 hastada (26.7%) negatif 
olarak değerlendirildi. Bcl-2 ekspresyonu açısından Grup A ve B hastalar ara-
sında fark saptanmadı. (p:0.475). Bcl-2 ile ER ekspresyonu arasında daha be-
lirgin olmak üzere hormon reseptör ekspresyonu arasında anlamlı ilişki sap-
tandı. (p<0.001, p:0.001). Ki-67 proliferasyon indeksi 8 hastada (17.8%) ne-
gatif, 10 hastada (22.2%) düşük ve 27 hastada (60%) yüksek olarak bulun-
du. Grup A ve Grup B hastalar arasında Ki-67 proliferasyon indeksi arasında 
ilişki saptanmadı. (p:0.555) Ki-67 proliferasyon indeksi ve bcl-2 ekspresyo-
nu arasında anlamlı ilişki saptanmadı. (p:0.736). Grup A hastalarda daha ile-
ri evre hastalık saptandı. Tartışma: DNA mikroarray çalışmaları meme kanse-
rinde farklı moleküler subtiplerin farklı klinik sonuçlarla ilişkili olduğunu gös-
termiştir. Çalışmamızda çok genç yaş hastalar (Grup A) ile diğer hastalarda 
(Grup B) immunohistokimyasal yöntemle araştırılan bcl-2 ve Ki-67 ekspres-
yonu arasında fark saptanmadı.  
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Abstract
Aim:  Incidence of breast cancer increases with age and nearly 85% of them 
are diagnosed after the age of 50. Clinical outcome of breast cancer  in 
young patients is worse than older patients. The aim of this study is to 
search  the  difference in expression of bcl-2 and Ki-67 between young and 
older women with breast cancer, and  if there is any; its clinical importance. 
Material and Method: This study includes 15 patients under the age of 35 
years old (Group A) and 30  patients over the age of 35 years (Group B)  all 
of whom were diagnosed with  breast carcinoma at Antalya Education and 
Research Hospital between 2008-2011. Results:  Bcl-2 expression was found   
positive in 33 (73.3%)  and negative in 12  (26.7%)  patients.  There were 
no difference in expression of bcl-2 between Group A and Group B patients 
(p:0.475). A meaningful  relationship was observed  between expression of 
bcl-2 and hormon receptors , being more significant in ER (p:0.001,p<0.001). 
Ki-67 proliferation index was found negative in 8 patients (17.8%), low in  10 
patients (22.2%) and high in  27  patients (60%). No relationship was found 
in Ki-67 proliferation index between Group A and Group B patients (p:0.555). 
There were no meaningful relationship between  Ki-67 proliferation index 
and bcl-2 expression (p:0.736). In Group A patients a more advanced stage 
disease was observed. Discussion: DNA microarray studies established that 
different  molecular  subtypes  in  breast  cancer  are  related  with  different 
clinical outcome. In our study, no difference was found in bcl-2 and Ki-67 
expression searched by immunohistochemical method , between very young 
(Group A) and  other (Group B) patients. 
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Introduction
Breast cancer is the neoplasia with the highest incidence in the 
female  population  worldwide.  Incidence  of  breast  cancer  in-
creases with age and nearly 85% of them are diagnosed after 
the age of 50 [1]. Very young patients (≤35 years) with breast 
cancer constitute 2.7% of all patients in western countries [2]. 
This ratio is between 10-25 % in Asian countries whereas it is 
established as 17% in our country [3;4].
 Clinical outcome of breast cancer in young patients is worse 
than older patients. Histologic grade and lymph node involve-
ment rate are found to be high and a lower hormone receptor 
expression is found in these patients at the time of diagnosis 
[5] . Genetic inheritance and BRCA1, BRCA2 mutations are ob-
served with a higher rate in young patients [6] .
Bcl-2 gene is firstly identified in patients with B cell follicular 
lymphoma establishing t(14;18) translocation but its expression 
is not related to this translocation. Bcl-2 increases the life cycle 
of the cell by inhibiting apopitosis and therefore causes the cell 
to come accross mutagenic factors more. In most of the human 
tumours a relation between bcl-2 expression and survival has 
been shown [7]. In patients with breast cancer, variable expres-
sion rates of Bcl-2 have been determined [8]. Besides, response 
to adjuvant endocrine therapy is found to be better in patients 
with bcl-2 expression [9;10]. 
Ki-67 is a marker that is widely used to determine the prolifer-
ating cells . Results of the studies that searched the relationship 
between Ki-67 expression and prognosis in patients with breast 
cancer are not clear. While Ki-67 proliferation index was found 
in association with bad prognosis in the majority of the studies, 
this association was not shown in other studies [11-13]. 
The aim of our study is to search the difference in expression 
of bcl-2 and Ki-67 between young and older women with breast 
cancer, and if there is any; its clinical importance.
Material and Method
Choosing the patients
This study includes the 15 female patients under the age of 
35 years, who were histopathologically diagnosed with invasive 
breast  carcinoma,  and  followed  up  at  the  Medical  Oncology 
Clinic of Education and Research Hospital between 2008 and 
2010. Thirty patients with the same diagnosis who were over 
the age of 35 years were chosen as the control group. Patients 
whose screening and clinical staging studies were completed 
were staged according to the 7th Staging System of the Ameri-
can Joint Committee on Cancer (AJCC). Patients’ files were ana-
lysed and information on age, gender, disease stage and other 
clinicopathological  characteristics  were  obtained.  Patients 
without histopathological diagnosis and patients whose initial 
treatments were started at another center and continued at our 
center were excluded from the study. 
 Immunohistochemistry
Tumor samples obtained right after the surgery were fixed in 
10% formaldehyde. After fixation, tumor samples were embe-
ded in paraffin. Then, histologic sections with a 4 µm thickness 
were obtained from paraffin blocks and were initially stained 
with hemotoxylin- eosine for assessment. 
The histologic sections were de-paraffinized in incubators at 
60°C for one hour. Afterwards, they were kept in xylene for 10 
minutes and in 100% alcohol for 5 minutes and then washed in 
water. Slides were kept in solution buffered with 10% citrate 
solution in microwave at maximum power (800 watts) for 15 
minutes. Then the power was decreased to the half and they 
were  kept  in  the  microwave  for  another  20  minutes.  Slides 
taken out of the microwave were kept in room temperature 
for 20 minutes. Endogenous peroxidase activity was removed 
by being kept in 3% hydrogen peroxide for 20 minutes. Slides 
washed in distilled water were treated with 3x5 PBS and pro-
tein blockage was dripped on them. Five minutes later, Ki-67 
and Bcl-2 antibodies were dripped on the slides without wash-
ing off the blockage. After being kept in primer antibody for 30 
minutes, they were taken into PBS and washed for 5 minutes. 
Afterwards, they were treated with biotinylated secondary an-
tibody for 20 minutes and washed in PBS for 5 minutes. They 
were kept with peroxidase conjugate antibody for 20 minutes. 
Then they were washed in PBS for 5 minutes. They were kept 
in chromogenous (DAB) for 5 minutes. Slides washed under tap 
water were adversely stained with haematoxylene. They were 
dehydrated, dried and mounted with entellane. 
For the staining of the samples Ki-67 protein, lyophilized mono-
clonal mouse antibody (clone B P53;12, 1:100, Invitrogen, Car-
mennillo,  Canada)  and  Bcl-2  onco-protein,  lyophilized  mouse 
monoclonal  antibody  (clone100/D5,  1:50,  Thermo  Scientific, 
Fremont, USA) were used. After the staining, slides were in-
spected under Nicon Eclipse 80 microscope.
Immunohistochemistry scoring
Slides were evaluated by two pathologists (ASA, DS) who did not 
know the clinical features of the patients. Each section that was 
stained by immunohistochemical method was examined under 
optical microscope. Bcl-2 expressions were assessed according 
to the cytoplasmic staining of the cells. Interval value for Bcl-
2 staining was accepted as 10%. If Bcl-2 staining was more 
than 10%, it was considered as positive expression, 10% or less 
staining was accepted as negative expression [7]. The areas 
with the highest nuclear staining were selected for Ki-67 and 
1000 tumor cells were counted. The ratio of tumor cells were 
calculated and their staining indices were identified as percent-
age. The interval value for Ki-67 was determined as 10%, and a 
staining index ≥ 10% was accepted as high, 1% to 10% staining 
was accepted as low, no staining was accepted as nil [14].
Statistical Analysis
Statistical analyses were performed using the SPSS software 
version 15. Differences between groups were inspected by us-
ing Chi-square and Man Whitney U tests. A p value of <0.05 was 
considered significant. 
Results
A total of 45 patients; 15 (33.3%) of whom were under the age 
of 35 years (Group A) and 30 (71.7%) of whom were over the 
age of 35 years (Group B) were enrolled in this study.
Median age was 32.4 (range 25-35 years) in Group A and 52.6 
(range 38-71 years) in Group B patients. Thirteen of the Group A 
patients had a diagnosis of invasive ductal carcinoma whereas 
2 of them had a diagnosis of invasive lobular carcinoma and 
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all of the Group B patients had a diagnosis of invasive ductal 
carcinoma. Expression of estrogen receptor (ER) and progester-
one receptor (PR) showed no difference between Group A and 
B patients (p:0.612, p:0.642). There were also no difference in 
expression of Her2 between the two groups (p:0.245). In Group 
A patients a more advanced stage disease was observed. (Table 1)
Bcl-2 expression was found positive in 33 (73.3%) and negative 
in 12 (26.7%) patients. There were no difference in expression 
of bcl-2 between Group A and Group B patients (p:0.475). No 
significant  relationship  was  found  between  Bcl-2  expression 
and T stage, lymph node status (p:0.849, p:0.746). A meaningful 
relationship was observed between expression of bcl-2 and hor-
mon receptors , being more significant in ER (p:0.001,p<0.001). 
ER expression was found as 90.9% in in Bcl-2 positive group 
and 40.7% in Bcl-2 negative group. Her-2 expression was not 
different in Bcl-2 positive and negative groups (p:0.06).
Ki-67  proliferation  index  was  found  negative  in  8  patients 
(17.8%), low in 10 patients (22.2%) and high in 27 patients 
(60%). The relationship of Ki-67 proliferation index between 
Group A and Group B patients was analysed by Man Whitney 
U  test  and  no  relation  was  found  between  the  two  groups 
(p:0.555). There were no meaningful relationship between Ki-67 
proliferation index and Bcl-2 expression (p:0.736). 
Discussion
Breast cancer is a heterogoneous disease in terms of clinical 
and pathological features and response to therapy. Convention-
al histologic classification of breast cancer does not suggest 
adequate  information  about  the  clinical  outcome.  Histologic 
type, grade and size of the tumour, expression of ER, PR and 
HER2 receptors, leymph node and metastasis status are consid-
ered as the important prognostic factors. Age of the patient is 
also considered as another prognostic factor. Age is related to 
prognosis independent of the performance score of the patient 
[15;16]. Breast cancer in very young premenopousal patients 
behave more agressively than postmenopousal patients with an 
older age. As in our study, many other studies established that 
these yuong patients have a disease of advanced stage at the 
time of diagnosis [17;21].
DNA  microarray  studies  established  that  different  molecular 
subtypes  in  breast  cancer  are  related  with  different  clinical 
outcome [22]. In our study, the role of the apopitotic marker 
Bcl-2 and the cell proliferative marker Ki67 in clinical progress 
between very young patients (Group A) and others (Group B) 
was searcehed and no difference was observed between the 
two groups. 
Although we found no difference in expression of ER, PR and 
HER2 between Group A and Group B patients, some studies sug-
gest that there is a difference in expression of these receptors 
between the two groups. In their large series Colleoni et al.. [23] 
found that ER and PR negativity were significant in patients 
with the age of 35 years when compared to patients over the 
age of 35. Also, rate of Ki-67 expression was found higher in 
these patients. Expression of HER2 was not found different. In 
their study, similiar to our study, the incidence of grade 3 tu-
mours was found higher in young patients. 
Bcl-2 expression had been searched in many types of cancer and 
in many of the studies it had been shown as a good prognostic 
factor. Varaible expression of Bcl-2 in normal duct epithelium, 
intraductal carcinoma and invasive ductal carcinoma was es-
tablished in different studies. In breast tissue, Bcl-2 expression 
was found as 96% in normal duct epithelium, 79% in intraductal 
carcinoma and 45% in invasive carcinoma. It was also shown 
that Bcl-2 expression has decreased in the development of car-
cinoma from the normal duct epithelium [24]. It was determined 
that Bcl-2 expression is related to well differantiation and ER 
expression, in breast cancer [25]. There are studies establishing 
the prognostic importance of Bcl-2 expression whereas some 
Table 1. Patient groups according to age
Grup A Grup B P value
Age 32.4 ( range 25-35) 52.6 (range 38-71)
Histology
Invasive ductal
Invasive lobular
13
2
30
0
Hormon Receptor
ER positive
PR positive
11 (73.3%)
10 (66.7%)
24 (80%)
22 (73.3%)
0.612
0.642
HER 2 positive 6 (%40) 7 (23%) 0.245
Sigara 4 (26.7%) 5 (16.7%) 0.429
Oks kullanımı 1 (6.7%) 1 (3.4) 0.627
T evresi
T1
T2
T3
T4
0
9 (60%)
6 (40%)
0
1 (3.3%)
26 (%86.7)
2 (6.7%)
1 (3.3%)
0.043
Nodal status
Positive
Negative
11 (73.3%)
4 (26.7%)
17 (56.7%)
13 (43.3%)
0.277
Histologic grade
Grade 1
Grade 2
Grade 3
0 
10 (66.7%)
3 (33.3%)
2 (6.7%)
31 (68.9%)
7 (23.3%)
0.499
Lymphovascular invasion 10 (66.7%) 15 (53.6%) 0.407
Perineural invasion 4 (28.6% 4 (15.4%) 0.320
Figure 1. Ki-67 staining in >10% of the tumour cells 
(Ki-67,  immunohistochemistry, method, X100)
Figure 2. Bcl-2 staining in >10% of the tumour cells 
(Bcl-2 , immunohistochemistry, X100)
Figure 3. Bcl-2 staining in >10% of the tumour cells 
(Bcl-2 , immunohistochemistry, X200)
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studies show vice-versa [26]. 
Yu et al. [27] published a study in which they evaluated 40 pa-
tients under the age of 35 and 40 postmenopousal patients over 
the age of 60 and found Bcl-2 expression as 19/40 in the group 
of young patients and as 30/40 in the group of older patients 
and showed a significant difference between the two groups. 
In their study, different from our study; e negative correlation 
was found between Bcl-2 expression and histologic grade and 
lymph node metastasis. A positive correlation was established 
between Bcl-2 expression and ER, PR expression, similiar to our 
study. In similiar studies concerning ductal carcinoma in situ 
(DCIS) cases, contrary to invasive ductal carcinoma, no differnce 
was determined between age groups and Bcl-2 expression [28].
Although many studies establish that Ki-67 proliferation index 
is higher in very young patients, we were not able to determine 
a similiar result in our study [29]. We think that this is due to the 
low number of patients under the age of 35 years , in our study. 
In  a  study  in  which  Bcl-2  expression  in  breast  cancer  was 
searched, Bcl-2 expression was found as 4.1% and ve Bcl-2 ex-
pression was found in correlation with a lower Ki-67 prolifera-
tion index. Besides, Bcl-2 expression was found in a lower rate 
in premenopousal patients , in the same study [30]. 
There is a few number of studies in which Bcl-2 expression and 
Ki-67 proliferation index have been evaluated together in very 
young patients with breast cancer. Choi et al. [34] searched 
103 patients between 25-45 years old with breast cancer and 
found Bcl-2 expression as 35.6% and Ki-67 proliferation index 
as 39.7% in their study. 
In conclusion, the bad progress in very young patients suggest 
that this subtype of breast cancer acquires a different tumour 
biology. Therefore, we think that it is important to demonstrate 
prognostic factors spesific to this group in order to plan proper 
treatment fort this group. 
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